The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Orion; Rakuten Aspyrian
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Merck Serono; Roche
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Gliknik; Janssen; Kura Oncology; MSD; Nanobiotix; Northern Biologics; Novartis; Orion; Pfizer; Rakuten Aspyrian; Shattuck Labs
Travel, Accommodations, Expenses - AstraZeneca; Merck Serono
BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study.
 
Sophie Cousin
No Relationships to Disclose
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Pharmamar; Roche
Research Funding - Bayer (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Irene Braña Garcia
No Relationships to Disclose
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; BioExcel; Daiichi Sankyo; Genentech/Roche; Janssen Oncology; Menarini Silicon Biosystems; Pfizer; Sanofi; Sierra Oncology
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Celgene; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sierra Oncology; Taiho Pharmaceutical
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); CellCentric (Inst); Daiichi Sankyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Medivation (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Orion (Inst); Sanofi (Inst); Sierra Oncology (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex
 
Christophe Le Tourneau
Honoraria - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck Serono; MSD; Nanobiotix; Novartis; Rakuten Medical; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck Serono; MSD; Nanobiotix; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Janssen Oncology; Merck
Speakers' Bureau - Bayer
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); E-therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Menarini (Inst); Merck (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
Other Relationship - Bristol-Myers Squibb
 
Jose Manuel Trigo
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; MSD; Takeda
Speakers' Bureau - AstraZeneca; Bayer; Eisai; MSD
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Christine L. Hann
Consulting or Advisory Role - Abbvie; Ascentage Pharma; Bristol-Myers Squibb; Genentech/Roche
Research Funding - Abbvie (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Merrimack (Inst)
Travel, Accommodations, Expenses - Abbvie/Stemcentrx; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb
 
Arun Azad
Honoraria - Amgen; Astellas Pharma; Bayer; Janssen; Novartis; Pfizer; Telix Pharmaceuticals; Tolmar
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Novartis; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Novartis
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Merck Serono; Sanofi
 
Seock-Ah Im
Consulting or Advisory Role - Amgen; AstraZeneca; Eisai; Hanmi; Lilly; medpacto; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca; Pfizer; Roche/Genentech
Travel, Accommodations, Expenses - Novartis; Roche/Genentech
Other Relationship - Roche
 
Geraldine Ferron-Brady
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline; GlaxoSmithKline
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Antara Datta
Employment - GlaxoSmithKline; Merck (I)
Stock and Other Ownership Interests - GlaxoSmithKline; Merck
 
Yuehui Wu
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Thierry Horner
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Brandon Edward Kremer
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Arindam Dhar
Employment - GlaxoSmithKline; PRA Health Sciences (I)
Stock and Other Ownership Interests - GlaxoSmithKline
 
Peter J. O'Dwyer
Consulting or Advisory Role - Array BioPharma; Genentech
Research Funding - Amgen; Array BioPharma (Inst); Bayer; BBI Healthcare; Bristol-Myers Squibb; Celgene; Five Prime Therapeutics; Forty Seven; Genentech; GlaxoSmithKline; H3 Biomedicine (Inst); Lilly/ImClone (Inst); Merck; Mirati Therapeutics; Novartis; Pfizer; Pharmacyclics; Taiho Pharmaceutical (Inst)
Expert Testimony - Bayer; Lilly
 
Geoffrey Shapiro
Consulting or Advisory Role - Almac Diagnostics; Angiex; Artios; Astex Pharmaceuticals; Atrin Pharmaceuticals; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Boehringer Ingelheim; Concarlo; Cybrexa Therapeutics; Daiichi Sankyo; Fusion Pharmaceuticals; G1 Therapeutics; Ipsen; Lilly; Merck Serono; Pfizer; Roche; Seagen; Sierra Oncology
Research Funding - Aileron Therapeutics (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CanBas (Inst); Cellceutix (Inst); Clovis Oncology (Inst); Covidien (Inst); Curis (Inst); Cyclacel (Inst); Esperas Pharma (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Sierra Oncology (Inst); Syros Pharmaceuticals (Inst); Tensha Therapeutics (Inst); Tesaro (Inst); Vertex (Inst)
Patents, Royalties, Other Intellectual Property - Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018; Provisional Patent #:62/538,319 Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition Filed: 7/28/17
Travel, Accommodations, Expenses - Bayer; Bicycle Therapeutics; G1 Therapeutics; Lilly; Pfizer; Sierra Oncology
 
Sarina Anne Piha-Paul
Consulting or Advisory Role - Merck
Research Funding - Abbvie (Inst); Alkermes (Inst); Aminex (Inst); Amphivena Therapetics, Inc. (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Incyte (Inst); Jacobio (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); New Link Genetics/BlueLink Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); TransThera Biosciences (Inst); XuanZhu (Inst)